Article
Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant.
Cancer genomics & proteomics - 1 Jan 2000
Li Junan, Cho Yu Kyoung, Sborov Douglas W, Phelps Mitch A, Hofmeister Craig C, Poi Ming J
Abstract excerpt
BACKGROUND/AIM: There exists considerably large interpatient variability in pharmacokinetic exposure of high dose melphalan in multiple myeloma patients with hematopoietic stem-cell transplantation. In this study, we aimed to evaluate the potential impacts of CYP3A4*1B (rs2940574) and CYP3A5*3 (rs776746) variations on pharmacokinetic properties of melphalan and clinical outcomes in multiple myeloma (MM) patients....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.